Traws Pharma Q2 2026 net loss $3.0M, no revenue; cash $5.0M, runway into Q1 2027

Traws Pharma, Inc.

Q2 2026 net loss $3.0M ($0.16/share) vs $0.9M loss in Q2 2025; no revenue vs $2.7M prior.
Cash $5.0M at June 30, 2026 vs $3.8M at Dec 31, 2025; expects runway into Q1 2027, may need more financing.
MHRA resubmission for tivoxavir marboxil expected Q3 2026; FDA clinical hold still unresolved, response planned by end 2026.
April 2026 financing delivered $10M upfront, potential $50M via warrants; shareholders approved Series B and C on July 8, 2026.
Six-month net loss $10.2M vs net income $20.6M in 2025 (due to $26.7M warrant gain).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.